510 related articles for article (PubMed ID: 29371588)
1. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis.
Nicolai S; Pieraccioli M; Peschiaroli A; Melino G; Raschellà G
Cell Death Dis; 2015 Dec; 6(12):e2010. PubMed ID: 26633716
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma: paradigm for precision medicine.
Irwin MS; Park JR
Pediatr Clin North Am; 2015 Feb; 62(1):225-56. PubMed ID: 25435121
[TBL] [Abstract][Full Text] [Related]
5. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
7. The connections between neural crest development and neuroblastoma.
Jiang M; Stanke J; Lahti JM
Curr Top Dev Biol; 2011; 94():77-127. PubMed ID: 21295685
[TBL] [Abstract][Full Text] [Related]
8. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
9. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
Carén H; Abel F; Kogner P; Martinsson T
Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets.
Katta SS; Nagati V; Paturi ASV; Murakonda SP; Murakonda AB; Pandey MK; Gupta SC; Pasupulati AK; Challagundla KB
J Control Release; 2023 May; 357():444-459. PubMed ID: 37023798
[TBL] [Abstract][Full Text] [Related]
11. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma.
Nakagawara A; Li Y; Izumi H; Muramori K; Inada H; Nishi M
Jpn J Clin Oncol; 2018 Mar; 48(3):214-241. PubMed ID: 29378002
[TBL] [Abstract][Full Text] [Related]
14. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
15. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
16. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
[TBL] [Abstract][Full Text] [Related]
17. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies.
Engler S; Thiel C; Förster K; David K; Bredehorst R; Juhl H
Cancer Res; 2001 Apr; 61(7):2968-73. PubMed ID: 11306475
[TBL] [Abstract][Full Text] [Related]
18. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
19. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.
Aygun N
Curr Pediatr Rev; 2018; 14(2):73-90. PubMed ID: 29380702
[TBL] [Abstract][Full Text] [Related]
20. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
